Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Broad Approach Required for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 06 Sep 2011
An immunoassay has been used to improve the diagnosis of histoplasmosis, which is often diagnosed by a combining antigen and antibody testing, as well as culture and pathology. More...


The sensitivity of the MVista Histoplasma antigen enzyme immunoassay (EIA) has been evaluated in disseminated histoplasmosis in patients with Acquired Immunodeficiency Syndrome (AIDS) and in the “epidemic” form of acute pneumonia.

Scientist at Indiana University (Indianapolis, IN, USA) collected serum and urine samples from 218 patients with histoplasmosis; 158 with disseminated disease and 60 with pulmonary infection, and 229 controls. The patients evaluated came from eight medical centers during the period from November 2004 through December 2007, and they were tested for Histoplasma and/or Blastomyces antigen at a commercial laboratory. The MVista Histoplasma antigen EIA was modified to permit quantification below the level of 0.6 ng/mL by incorporating 0.2 ng/mL and 0.4 ng/mL calibrators and removing those of ≥19 ng/mL. Serum specimens were treated with 4% EDTA at 104 °C before testing.

In the group with disseminated histoplasmosis, the rate of antigenuria, the presence of the specific antigen in the urine, was 91.8%. Sensitivity for the presence of the specific antigen in the serum, antigenemia, was similar. Culture findings were positive in 74.2% of cases, and similar rates were seen with pathology (76.3%) and antibody testing (75.0%). The sensitivity of the test in pulmonary cases varied, as antigenuria was positive in 83.3% of acute cases, in 87.5% of chronic cases, but in only 30.4% of subacute cases. Conversely, antibody results were positive in 66.7%, 95.1%, and 83.3% of those three categories, respectively. The control group included 30 subjects with blastomycosis, and the histoplasmosis tests were 90% cross-reactive in this group. However, the histoplasmosis antigen-enzyme immunoassay was 99% specific when tested in healthy subjects and those with nonfungal infections.

MVista Histoplasma antigen quantative sandwich EIA is a product of MiraVista Diagnostics (Indianapolis, IN, USA) where the laboratory analysis was carried out. Chadi A. Hage, MD, the senior author of the study, and his colleagues concluded that their study supports a broad approach, using antigen testing of urine and serum samples, antibody testing, culture, and pathology for diagnosis of disseminated or pulmonary histoplasmosis. The study was published online on August 2, 2011, in the journal Clinical Infectious Diseases.

Related Links:

Indiana University
MiraVista Diagnostics




Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.